Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

ByKevin W. Su, MD,Cary P. Gross, MD,Nicholas S. Downing, MD,Kerin B. Adelson, MD,Joseph S. Ross, MD, MHS

July 28th 2017

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Published: February 12th 2016 | Updated:
Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion
Published: July 28th 2017 | Updated:

Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market

Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices

Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health

FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder

A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin